Ipamorelin
Selective GHS-R1a agonist (ghrelin receptor / 'GH secretagogue')
At a glance
What it is: Selective GHS-R1a agonist (ghrelin receptor / 'GH secretagogue').
Primary research applications:
- Claimed: GH release for body composition and recovery
- Historical: postoperative ileus (failed Phase 2/3)
Editorial summary: Ipamorelin is a relatively selective GH secretagogue that reliably triggers GH release in humans. Its historical pharmaceutical development (for postoperative ileus) failed in Phase 2/3. Current popularity is off-label / grey-market.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide first described by Novo Nordisk in 1998 as a selective growth hormone secretagogue. It binds the GHS-R1a (ghrelin) receptor in the pituitary to stimulate GH release, with minimal effect on cortisol and prolactin at physiologic doses — a cleaner profile than older secretagogues like GHRP-6.[1]
Ipamorelin was developed by Helsinn as HLN-10085 for postoperative ileus (slow GI function after surgery). Phase 2 trials did not meet primary endpoints, and clinical development was discontinued. It is not FDA-approved.
Mechanism of action
Ipamorelin mimics ghrelin's action at the pituitary GHS-R1a receptor, causing a pulse of GH release. Unlike older secretagogues (GHRP-2, GHRP-6), it doesn't meaningfully stimulate cortisol, ACTH, or prolactin at typical doses.
When combined with a GHRH analog (CJC-1295 or Sermorelin), the two mechanisms act synergistically — GHRH provides the 'go' signal and ghrelin-mimetics amplify the pulse.
What the research shows
The peer-reviewed literature on Ipamorelin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Stimulates endogenous GH release | Clear in human PK studies | Supported |
| Produces fewer side effects than GHRP-2 or GHRP-6 | Mechanistically and pharmacologically cleaner | Supported |
| Builds muscle / reduces fat in humans | No body-composition RCTs | Preliminary |
| Synergizes with CJC-1295 | Consistent with different receptor mechanisms; well-demonstrated in pharmacology | Supported |
| Works to treat postoperative ileus | Phase 2 failed | Unsupported |
Reported user experiences
How the research describes administration
In the published pharmacology literature, subcutaneous injection once to multiple times daily has been used, typically in combination with GHRH analogs.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Ipamorelin is the cleanest-tolerated GH secretagogue in common grey-market use. It works pharmacologically as advertised — it raises GH. Whether this translates to the body composition and anti-aging benefits claimed is unproven by RCTs. Stacking with CJC-1295 or Sermorelin is the common pattern and has a pharmacologic rationale.
Frequently asked questions
Is ipamorelin better than CJC-1295?
They work by different mechanisms (ghrelin receptor vs. GHRH receptor). They're complementary rather than alternatives — most grey-market stacks combine them.
Why was ipamorelin's pharmaceutical development discontinued?
Helsinn's Phase 2 trials for postoperative ileus did not meet primary endpoints. The indication was commercial, not a reflection of the GH-releasing mechanism, which worked as expected.
Does ipamorelin increase cortisol?
At typical doses, no — this is what distinguishes it from older secretagogues like GHRP-2 and GHRP-6. At very high doses the selectivity may erode.
Is ipamorelin safe long-term?
Short-term human safety looks reasonable from the available pharmacology. Long-term data is absent. Elevated IGF-1 over years carries theoretical cancer and glucose-metabolism considerations.
Does ipamorelin cause hunger like GHRP-6?
Generally not — this is one of the main selectivity advantages. GHRP-6 strongly stimulates appetite through ghrelin receptor effects that ipamorelin largely avoids.
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. https://pubmed.ncbi.nlm.nih.gov/25331029/